Novo Nordisk's Etavopivat Meets Co-primary Goals In Phase 3 HIBISCUS Trial In Sickle Cell Disease

Novo Nordisk reported topline results from the phase 3 HIBISCUS trial of once-daily oral Etavopivat in sickle cell disease, and the study met both co-primary endpoints. The drug also showed a greater haemoglobin response than placebo, a positive efficacy signal for the company’s pipeline.

Analysis

Novo Nordisk reported topline results from the phase 3 HIBISCUS trial of once-daily oral Etavopivat in sickle cell disease, and the study met both co-primary endpoints. The drug also showed a greater haemoglobin response than placebo, a positive efficacy signal for the company’s pipeline.